Last reviewed · How we verify
NCT03786913
Quantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases
trial testing Quantitative muscle ultrasound measurements in Inflammatory Myopathy in 48 participants. Completed in 2 February 2019.
2 February 2019
Quick facts
| Lead sponsor | Benha University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 8 March 2016 |
| Primary completion | 2 February 2019 |
| Estimated completion | 2 February 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Quantitative muscle ultrasound measurements
Conditions studied
- Inflammatory Myopathy — all drugs for Inflammatory Myopathy →
- Duchenne Muscular Dystrophy — all drugs for Duchenne Muscular Dystrophy →
Sponsor
Benha University
Who can join
Adults 2 to 16, any sex, with Inflammatory Myopathy or Duchenne Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study is to Assess skeletal muscle structural status in children with inflammatory myositis and Duchenne muscular dystrophy using musculoskeletal ultrasound and to perform a longitudinal follow up of these changes over 2 years and to assess the relation between these findings with clinical parameters, functional scales, biochemical and electromyographic tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03786913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammatory Myopathy
Currently open trials in the same condition.
- NCT07413341 — A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases · Phase 1 · recruiting
- NCT07236762 — An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · Phase 1 · recruiting
- NCT07236801 — Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases · Phase 1 · recruiting
- NCT07123519 — A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases · Phase 1 · recruiting
- NCT07104721 — A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · Phase 1 · recruiting
Other Benha University trials
Trials by the same sponsor.
- NCT07526675 — Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer · NA · not yet recruiting
- NCT07480031 — Determination of the Optimal Inspiratory Pressure to Decrease Incidence of Gastric Insufflation With Adequate Ventilatio · NA · not yet recruiting
- NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
- NCT07467356 — Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip · Phase 3 · recruiting
- NCT07300787 — miRNA in Pediatric Gastritis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03786913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Benha University
- Last refreshed: 8 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03786913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing